The present invention discloses non peptide prokineticin 1 receptor agonists and their uses for the treatment of PKRl mediated disorders, in particular for the treatment of vascular diseases, neurodegenerative diseases, diseases involving impaired gastrointestinal motility, obesity, Kallmann syndrome, normosmic hypogonadotropic hypogonadism and disturbances of circadian rhythm, and to prevent or limit the toxicity, in particular the cardiotoxicity and neurotoxicity, of drugs. The present invention also discloses a prokineticin receptor-1 agonist for use for promoting the differentiation of cardial epicardin+ progenitor cells into cardiomyocytes in a subject affected with a cardiac disease and/or the differentiation of renal epicardin+ progenitor cells into vasculogenic and/or glomerular cells in a subject affected with a renal disease. The present invention further discloses a prokineticin receptor-1 agonist for use for treating or preventing insulin resistance, in particular associated with type II diabetes
